Podcasts about apellis pharmaceuticals

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year's meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apellis Pharmaceuticals). What did microperimetry findings reveal about long-term dosing with C3 inhibition? Join us in this episode to find out. 

Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.

Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.

 This panel discussion on startup commercial strategy explores key elements and insights from industry leaders, Paul Bresge, Aziz Mottiwala, Todd Pinkney, Cari Stone and Adam Szaronos, offering a comprehensive view of the journey from regulatory approval to commercialization. Beth Marsh, Lead of Sales and Marketing at Apellis, sets the stage by emphasizing the importance of early consideration of commercial strategy. Key topics covered in the discussion include:Early Commercial StrategyElements of Robust StrategyRaising Institutional FundingEvolution of StrategiesFuture AnticipationDon't miss out – listen now for a comprehensive view of navigating the complexities of startup success!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein OcclusionsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.DisclosuresRobert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.Other Financial or Material Support in the form of royalties from Springer Publishers.Medical DirectorKristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein OcclusionsThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.DisclosuresRobert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.Other Financial or Material Support in the form of royalties from Springer Publishers.Medical DirectorKristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Here are the key points from today's news:GSK has partnered with Chongqing Zhifei Biological Products to expand sales of its shingles vaccine, Shingrix. The company aims to double sales of the vaccine by 2026.Apellis Pharmaceuticals reports steady demand for its new eye drug, Syfovre, despite safety concerns. Prescriptions for the drug have increased in August after a period of side effect investigations.Amgen has completed its $28 billion acquisition of Horizon, despite challenges from the FTC. The deal was delayed due to concerns about product "bundling," but Amgen agreed to requirements to address these concerns.Merck has released data showing a survival benefit for early treatment with its immunotherapy drug, Keytruda, in the perioperative setting. An approval decision is expected later this month.The medtech sector is facing several financial challenges, including declining stock prices, mergers and acquisitions, investment, and revenues, according to a report from consulting firm EY.Walgreens has announced that Tim Wentworth, a former executive at Cigna and Express Scripts, will become its new CEO starting from October 23.Novo Nordisk has ended a Phase III kidney outcomes study of its drug semaglutide early due to strong efficacy signals. The positive results suggest that semaglutide may have a beneficial impact on kidney function.Biotech bankruptcies have been on the rise in 2023, with a record high of 28 bankruptcies in the sector so far this year.Roche's subcutaneous version of its multiple sclerosis drug Ocrevus has shown promise in a Phase III trial. The subcutaneous formulation performed comparably to the intravenous version of the drug.Biotech company Sana has announced staff layoffs and a refocus on its ex vivo cell therapy platform. The company will be reducing its workforce by 29% and reallocating resources to prioritize its hypoimmune platform.These developments highlight both positive and challenging trends in the Pharma and Biotech industry. Stay tuned for more updates on the latest news.

Dr. Mike Yeadon is a retired Vice President and Chief Scientific Officer at Pfizer's Pharmaceutical Company, and researcher of immunology and respiratory disease. Afterwards he was the Consulting Acting Chief Scientific Officer at Apellis Pharmaceuticals. He has been critical of the WHO, the British and American governments' response to the Covid-19 pandemic, its understanding of immunity, the use of the PCR test, and the lack of proper safety procedures for experimental mRNA vaccines. Dr. Yeadon trained as a biochemist and pharmacologist, obtaining his PhD from the University of Surrey in UK

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.    How did patients fare in the GALE extension study, which assessed the safety and efficacy of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) for geographic atrophy? Nathan C. Steinle, MD, shares the results of the first 6 months of GALE, in which patients who received treatment for 24 months in DERBY/OAKS continued with therapy—and in which patients who had received sham treatment for 24 months were switched over to treatment.    Paul Hahn, MD, PhD, joined us in our mobile studio in Seattle to share data from a matching-adjusted indirect comparison of pegcetacoplan and avacincaptad pegol (Izervay, Iveric Bio). What did he and his team find?    This is episode 2 of 2 covering the 2023 ASRS Annual Meeting. Go back in your feed to listen to episode 1.  

In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, co-founder and chief executive officer/president of Apellis Pharmaceuticals. The two experts discussed the company's landmark therapy, pegcetacoplan (SYFOVRE™), for geographic atrophy and the decades-long journey toward FDA approval. Sheth also asked about Francois' evolving role in the company and the interplay between being a scientist, clinician, and corporate executive. The experts also touched on how the GA treatment landscape might evolve over the next few years and what will shape the future of retina.  Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com. 

US equity futures are indicating a lower open as of 05:00 ET. European equity markets are firmer, following mixed markets in Asia. Oil is dominating the headlines after OPEC+ made the surprise decision to cut daily crude output by more than 1M barrels. A stabilization in the global banking sector and bond markets has been attributed to the recent rebound in equities and risk assets.Companies Mentioned: World Wrestling Entertainment, Endeavor Group, Apellis Pharmaceuticals, McDonald's, Baidu

In this episode, Ayesha talked about the FDA approval of Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy, a leading cause of blindness. The condition is an advanced form of dry age-related macular degeneration (AMD) for which there have been no treatment options up until this recent approval. Hear more about the drug, including some questions about its clinical benefit.Ayesha also talked about the FDA's emergency use authorization (EUA) of Lucira Health's over-the-counter (OTC) combination COVID-19 and flu diagnostic that can be administered at-home. The molecular PCR test is the first at-home combination test that can differentiate and detect the Influenza A, B and SARS-CoV-2 viruses in 30 minutes or less. The editorial team discussed the utility of the test, including settings in which they may be useful in and whether they may even be needed at all.Read the full articles here:Apellis' Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical BenefitFDA Authorizes First At-Home Combination COVID and Flu TestFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice. 

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Allison W. Shuren, JD, MSN. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :30 News and notes with John and Jim 1:20 On the return of in-person medical meetings 1:28 Byooviz, biosimilar to Lucentis, to be available July 1 2:40 First patient dosed in the phase 3 registrational COMET-2 study of AR-15512 for the treatment of dry eye disease signs and symptoms 5:50 Apellis Pharmaceuticals submitted a new drug application to the FDA for intravitreal pegcetacoplan, for the treatment of geographic atrophy secondary to age-related macular degeneration 9:04 Kala enters agreement to sell commercial portfolio to Alcon 11:30 FTC opens investigation into pharmacy benefit managers 13:30 Introduction of Allison W. Shuren, JD, MSN 15:45 The interview 17:44 The FTC investigation of pharmacy benefit managers and other enforcement trends 18:12 Have you seen an increase in cases against practices and industry and if so, why? 19:36 Prior authorization and trends in reduced access to care 22:12 What advice would you give to practices who are considering selling to private equity? 23:50 What advice are you giving to the private equity buyers? 25:32 What advice would you give to young surgeons coming out now to succeed in the future? 27:19 Introducing the next guest, David Chang, MD 30:55 Allison W. Shuren, JD, MSN, is a partner at the law firm Arnold & Porter, where she co-chairs the life sciences and healthcare regulatory practice and advises a wide range of health care clients on regulatory, compliance, enforcement and legislative matters. Before starting her career as a lawyer, she was a practicing critical care pediatric nurse practitioner. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Shuren via email at allison.shuren@arnoldporter.com. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Could photobiomodulation soon be a therapeutic option for patients with dry AMD? Researchers in the LIGHTSITE III study are working toward finding out. We spoke with Marion Munk, MD, PhD, about the details from a study that evaluated the Valeda Light Delivery System (LumiThera) in patients with dry AMD. Were patients able to safely realize any improvement to visual function?  And we checked in with Roger Goldberg, MD, MBA, who detailed the 18-month findings of the DERBY and OAKS studies, a pair of phase 3 clinical trials evaluating the safety and efficacy of pegcetacoplan (APL-2, Apellis Pharmaceuticals) in patients with geographic atrophy. The studies' primary endpoint was at 1 year. What did they find after an additional 6 months? Stick here to find out. 

March 11, 2022. Dr. Nancy Holekamp, a retinal specialist, clinical trial investigator, and key opinion leader in the retinal disease space, discusses new therapies and research for wet and dry age-related macular degeneration and some emerging treatment approaches for inherited retinal diseases. This episode is sponsored by Apellis Pharmaceuticals.

Birva K. Shah, OD,  says developing a professional network is one of the most important steps an OD can take if she wants to make a career switch like hers. She's now a medical science liaison in ophthalmology at Apellis Pharmaceuticals. She explains the research and preparation she went through to find opportunities in this career option she had not even imagined when she graduated from optometry school. 

How Broadcom (AVGO) plans to keep up with chip demand from smartphone makers and continue making smart acquisitions, our guest is JoAnne Feeney, portfolio manager at Advisors Capital Management. The keys to Purple Innovation's (PRPL) success disrupting the mattress industry and managing inflation. How Community Health Systems (CYH) is getting hospital patients to pay their bills. Apellis Pharmaceuticals (APLS) wins approval for a drug to treat a rare blood disease. The Drill Down with Cory Johnson offers a daily look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

Cedric Francois, MD, PhD, Co-Founder & CEO of Apellis Pharmaceuticals, gives an overview of paroxysmal nocturnal hemoglobinuria (PNH).

Cedric Francois, MD, PhD, Co-Founder & CEO of Apellis Pharmaceuticals, discusses the results of the PEGASUS study evaluating the efficacy and safety of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.

There's a lot of positive spin being put on the news that Papa John's International Inc. is opening a new global headquarters in Atlanta, instead of Louisville. And hey look, we realize the chamber of commerce and the mayor's office can't publicly scorn the company for this decision. They have to be diplomatic and congratulate Papa John's on their success and potential growth.But we don't have to be diplomatic. We're just going to come right out and say that this is the latest (and largest) company to decide that there's greener pastures out there than Louisville if you're looking to grow globally. It's a troubling trend we talk about on this week's Access Louisville podcast. Apellis Pharmaceuticals is another recent departure as our list of public companies continues to shrink in recent years. We also saw Yum Brands Inc. move the top brass out of Louisville several years back.On the show, we chat about the transition at Papa John's that led to this decision, including the appointment of its CEO Rob Lynch. We also talk about the way this news was received by leaders in Louisville. Only a few, including founder John Schnatter called it disappointing.Access Louisville is a weekly podcast from Louisville Business First. If you like what you hear be sure to check us out on popular podcast services.

This week on the Access Louisville podcast we discuss the news that Apellis Pharmaceuticals is leaving town. This was a promising pharmaceuticals company that’s been growing here for the last decade or so. At the beginning of 2020 it moved its operations to Boston — another hit to Louisville’s public company scene. Reporter Chris Larson tells us about the move and the recent history of local public companies — at least, those traded on the New York Stock Exchange and the NASDAQ — disappearing in mergers or other moves.We also discuss a new flavor of Girl Scout cookies, which are made here in Louisville. And Reporter Haley Cawthon tells us about a recent acquisition for Yum Brands Inc.Access Louisville is a weekly podcast from Louisville Business First. Digital Editor David A. Mann and Design/Multimedia Editor Brooke Timmons also host the show this week. Here’s a rundown of the show::55 — A new Girl Scout cookie flavor is here.5:05 — Apellis Pharmaceuticals is leaving Louisville12:54 — Yum Brands makes an acquisition

Drs. Daniel Chao and Ferhina Ali join the podcast for a sneak peek at the January 2020 issue of Retinal Physician (found at http://www.retinalphysician.com) discussing topics such as integration of imaging software with EHR, swept-source OCT angiography applications, intraoperative OCT, and optogenetics. Want to be on the podcast? Now is your chance! Vit-Buckle Society is looking for videos to be presented on the podium during the Complications session of the Annual Meeting in Miami March 26-28 2020. Videos can be identifying or anonymous but should include text descriptions and be 1-4 minutes in length. The top five entries will be invited to come on the podcast for a one-on-one interview discussing the case. Submit entries now to paulapecen@gmail.com or mklufas@gmail.com Dr. Sridhar is a consultant for Alcon, Alimera, and Oxurion. Dr. Ali is a consultant for Genentech and Voyant Biotherapeutics. Dr. Chao is a consultant for Recens Medical, DTXPharma, Allergan, Visgenx, and Zilia and receives research funding from the National Eye Institute, Bright Focus Foundation, Clearside Biomedical Inc., Chengdu Pharmaceuticals, Opthea Ltd, Genentech, and Apellis Pharmaceuticals. You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio.

ay is joined by Dr. Amy Schefler, Dr. Chirag Shah, and Dr. Nathan Steinle for a panel discussion regarding how to best approach maximizing retina clinic efficiency and other issues new retina attendings in practice may encounter. You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio. Financial Disclosures: Dr. Sridhar: Consultant for Alcon, Alimera Sciences, and Thrombogenics. Dr. Schefler: Consultant for Allergan, Aura Biosciences, Castle Biosciences, Genentech, and Regeneron. Receives research support from Aura Biosciences, Castle Biosciences, Genentech, and Regeneron. Dr. Shah: Consultant for Regeneron. Receives research support from NIH, Alcon, Genentech, Novartis, Regeneron, Apellis, and Ellex. Dr. Steinle: Consultant for Apellis Pharmaceuticals, Alimera Sciences, Regeneron Pharmaceuticals, Genentech, Regenxbio, Carl Zeiss Meditec, Regenerative Patch Technologies, Novartis, and Vortex Surgery. Speaker’s Bureau for Alimera Sciences, Genentech, Regeneron Pharmaceuticals, NotalVision; and Novartis. Receives research support from Carl Zeiss Meditec, Genentech, Regeneron Pharmaceuticals, and Novartis. Investor in Vortex Surgical and Garbha Health.

The complement system, part of the immune system, has long been used as a target for interventions in certain rare disease. Apellis Pharmaceuticals is developing therapies to treat rare blood and kidney diseases, but by targeting a different part of the complement system than available therapies do today. We spoke to Cedric Francois, co-founder, president and CEO of Apellis, about the complement system, Apellis’ approach, and why he thinks this will lead to better therapies for these rare diseases.

Tim Sullivan, CFO of Apellis Pharmaceuticals, gives an inside look at what it takes to be the CFO of a development-stage biotech company, and what business skills someone needs to succeed in that type of position. Leadership tip from Tim Sullivan.

In the latest edition of the Metro Startup Launcher podcast, I interview Ted Smith, CEO of Revon Systems, Inc. Ted has been a major influencer of our startup community in many ways for quite a while.  He's been a researcher, an entrepreneur, and even the Louisville Metro Director of Innovation.  Now Ted is the CEO of Revon System, a leading developer of software applications for the treatment of chronic health conditions. Ted, Revon Systems, and their associated colleagues at Apellis Pharmaceuticals are doing amazing things to give Louisville a big star on the map in the world of healthcare innovation.  They're setting an excellent example of how we all should think much bigger about what we can accomplish right here in the Midwest. In this interview you'll learn: ♦ What is Revon, and how could their technologies improve healthcare? ♦ What's the background of Revon and Apellis? ♦ How should a local entrepreneur think about raising capital in Louisville for big vision, risky, world-changing projects? ♦ What combination of innovator and business person makes for a great entrepreneur? ♦ How does luck and timing factor into the business world? ♦ What was Ted's route to becoming an entrepreneur? ♦ How can our startup community improve?